Scotland backs diabetes drug
19 March 2010
People in Scotland with type-2 diabetes now have access to a wider choice of treatments after saxagliptin (Onglyza) was accepted for use within NHS Scotland.
The Scottish Medicine Consortium approved restricted use of the drug in adult patients with type-2 diabetes as an add-on combination therapy with metformin, when metformin plus exercise does not achieve adequate glycaemic control.
The dipeptidyl peptidase4 inhibitor is restricted to use when the addition of sulphonylureas is not deemed to be appropriate.
Its use represents an alternative to other agents such as thiazolidinediones, the SMC said in a statement.
However, the SMC said it could not recommend the use of saxagliptin in combination with sulphonylureas or thiazolidinediones.
Additional Information
Latest jobs Jobs web feed
- Salaried GP The Practice plc £75-85k FTE +NHS pension, Ely or Leicester
- Regional Clinical Leads The Practice plc Salary £95-105k FTE + NHS pension, Leicester or Sheffield
- dr-locums are currently recruiting locum GP's in the East of England who are interested in Out Of Hours work. dr-locums Earn up to £1,000.00 a day, East Anglia
- Locum GP's in Luton. dr-locums £70.00ph - £105.00ph, Luton
- Locum GP's in Hertfordshire dr-locums £70.00ph - £105.00ph, Hertfordshire
- Locums GP Wolverhampton Pegasus Medical £70 per hour, Wolverhampton and West Midlands long term
Most read
Most commented
MIMS Drug Search
Possible searches include drugs (by brand, generic ingredient or drug class), diseases and more.
